Ting K, Gill T K, Keen H, Tucker G R, Hill C L
Department of Rheumatology, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia.
School of Medicine, The University of Adelaide, Adelaide, South Australia, Australia.
Intern Med J. 2016 May;46(5):566-73. doi: 10.1111/imj.13006.
Despite gout and hyperuricaemia being major comorbid health issues worldwide, there is a knowledge gap regarding their impact in the Australian community.
To determine the prevalence and associations of self-reported medically diagnosed gout and hyperuricaemia in an Australian population-based cohort.
The North West Adelaide Health Study is a longitudinal cohort study consisting of three stages of data collection. Each stage comprised a self-complete questionnaire, clinic assessment and computer-assisted telephone interview. In Stage 3 (2008-2010), participants were asked if a doctor had ever diagnosed them with gout. Additional data included demographics, comorbidities, laboratory data and Short Form 36 (SF-36). Participants were defined as having gout if they had self-reported medically diagnosed gout or were taking any gout-specific medication (allopurinol, colchicine, probenecid). Hyperuricaemia was defined as a serum uric acid (SUA) level >0.42 mmol/L in men and >0.34 mmol/L in women.
The overall prevalence of gout was 5.2%. Males were significantly more likely to have gout than females (8.5 vs 2.1%, P < 0.001). The overall prevalence of hyperuricaemia was 16.6%, with being male again identified as a significant risk factor (17.8 vs 15.4%, P < 0.01). Both gout and hyperuricaemia were associated with male sex, body mass index and renal disease after multivariable adjustment. There was no significant difference reported in quality of life (mean SF-36) scores in participants with gout compared to unaffected individuals.
The prevalence of gout and hyperuricaemia is high in the South Australian population. This study emphasises the need for optimal diagnosis and management of gout in Australia.
尽管痛风和高尿酸血症是全球主要的合并健康问题，但在澳大利亚社区中，人们对其影响的认知存在差距。
确定澳大利亚基于人群的队列中自我报告的经医学诊断的痛风和高尿酸血症的患病率及相关性。
西北阿德莱德健康研究是一项纵向队列研究，包括三个数据收集阶段。每个阶段都包括一份自我填写的问卷、临床评估和计算机辅助电话访谈。在第三阶段（2008 - 2010年），询问参与者医生是否曾诊断他们患有痛风。其他数据包括人口统计学、合并症、实验室数据和简短健康调查问卷（SF - 36）。如果参与者自我报告经医学诊断患有痛风或正在服用任何痛风特异性药物（别嘌醇、秋水仙碱、丙磺舒），则被定义为患有痛风。高尿酸血症定义为男性血清尿酸（SUA）水平>0.42 mmol/L，女性>0.34 mmol/L。
痛风的总体患病率为5.2%。男性患痛风的可能性显著高于女性（8.5%对2.1%，P < 0.001）。高尿酸血症的总体患病率为16.6%，男性再次被确定为显著的危险因素（17.8%对15.4%，P < 0.01）。经过多变量调整后，痛风和高尿酸血症均与男性性别、体重指数和肾脏疾病相关。与未受影响的个体相比，痛风患者的生活质量（平均SF - 36）得分没有显著差异。
南澳大利亚人群中痛风和高尿酸血症的患病率很高。本研究强调了澳大利亚对痛风进行最佳诊断和管理的必要性。
